Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Prothena Corporation plcNASDAQ: PRTA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 98.2%

Gross margin was 98.2% in Q1 FY2026, down 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 46.8%, down 53.2 pp year over year. Over 3 fiscal years it narrowed by 38.2 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.2%+4483.9 pp QoQ
Last fiscal yearDec 2025
61.8%-38.2 pp YoY
LTMMar 2026
46.8%-53.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.8 pp——
1 year-38.2 pp——
3 years-38.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
61.8%
Year-over-year change
-38.2pp

Gross Margin vs competitors

How PRTA compares with its peers on the latest reported figures

  • PRTA's LTM Mar 2026 gross margin of 46.8% is the 3rd highest of the 4 companies compared; the peer median is 67.7%.
  • Its year-over-year change of -53.2 pp is the lowest of 3, against a peer median of -2.4 pp.
  • Over three fiscal years its change of -38.2 pp compares with a peer median of -3.6 pp.
PRTA Competitors Peer median
Gross Margin for PRTA and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
BIIBBiogen Inc.LTM Jun 202667.7% -4.8 pp-7.1 pp
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-61.0% ——
ANNXAnnexon, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
PMNProMIS Neurosciences, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PRTA) 67.7%-2.4 pp-3.6 pp

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.